The trajectory of companies tied to the drug's legacy presents a challenging investment scenario . While the initial surge generated substantial profits , generic copies have significantly diminished revenue. Investing in associated pharmaceutical firms now requires a thorough assessment of intellectual property rights , evolving healthcare shifts